TuHURA Biosciences, Inc./NV
HURANasdaqHealthcare · Pharmaceutical Preparations · NV · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | — | — | — |
| Operating income | — | — | — | — | — | — |
| Net income | −$30.1M | −$21.7M | −$29.3M | −$22.7M | −$38.3M | −$9.1M |
| Total assets | $27.4M | $20.0M | $4.4M | $15.9M | $13.5M | $2.9M |
| Total liabilities | $6.4M | $5.4M | $5.9M | $4.2M | $3.0M | $2.7M |
| Equity | $20.9M | $14.6M | −$1.6M | $12.3M | $10.6M | $263,000 |
| EPS (diluted) | $-0.63 | $-1.21 | $-2.47 | $-25.80 | $-1.60 | $-0.87 |
| Shares out. | 43.7M | 55.66B | 1.7M | 80.8M | 43.2M | 23.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −143.6%
- Return on assets
- −109.9%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 23.5%
- Debt / equity
- 0.31×
- Book value / share
- $0.48
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Accruals / assets
- −8.9%clean
- Piotroski F-Score
- 3/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 2 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Sep 30, 2024
- NT 10-Kmissed a reporting deadline ↗Sep 28, 2012
- NT 10-Qmissed a reporting deadline ↗May 16, 2012
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Recruitingreadout ~2026-05-31IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
- Phase 2/3Recruitingreadout ~2027-03-31Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Highbridge Capital Management LlcPassive (13G)Feb 17, 2026
- Vanguard Group IncPassive (13G)Oct 31, 2025
- Kp Biotech Group LlcPassive (13G)Aug 14, 2025
- Ca Patel F&F Investments, LlcPassive (13G)Aug 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Bianco James A.Officer — Chief Executive Officer | May 28, 2026 | Gift | 150,000 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 8.0M | 13.8 | -3.3% |
| Apr 30, 2026 | 8.3M | 7.8 | -0.7% |
| Apr 15, 2026 | 8.3M | 4.7 | +11.1% |
| Mar 31, 2026 | 7.5M | 10.9 | +4.0% |
| Mar 13, 2026 | 7.2M | 8.3 | +3.4% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- New financial obligationMay 29, 2026
- Results of operations · Regulation FD disclosureMay 15, 2026
- Entered a material agreement · New financial obligation · Unregistered equity sale · Regulation FD disclosureApr 22, 2026
- Director / officer change · Other material eventApr 8, 2026
- Results of operationsApr 1, 2026
- Delisting / listing-standard noticeJan 30, 2026
- Entered a material agreement · Other material eventDec 10, 2025
- Entered a material agreement · New financial obligationDec 5, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.